Find clinical trials for Multiple Myeloma in Montréal, QC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Multiple Myeloma trials near Montréal, QC, CAN:
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
Montreal, Quebec, Canada and 145 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Phase 1, Phase 2
Montreal, Quebec, Canada and 48 other locations
of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...
Phase 2
Montreal, Quebec, Canada and 40 other locations
phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma...
Phase 1, Phase 2
Montreal, Quebec, Canada and 24 other locations
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical ben...
Phase 4
Montréal, Quebec, Canada and 3 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Montréal, Canada and 139 other locations
as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts:...
Phase 1
Montreal, Quebec, Canada and 14 other locations
(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...
Phase 2
Montreal, Quebec, Canada and 48 other locations
of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple...
Phase 2
Montréal, Quebec, Canada and 47 other locations
provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...
Phase 2
Montreal, Quebec, Canada and 72 other locations
Clinical trials
Research sites
Resources
Legal